Stockscreener 앱 받기
210.32
1.06%
-2.4078
전일 마감가:
$212.73
열려 있는:
$209.465
하루 거래량:
308.86K
Relative Volume:
0.22
시가총액:
$30.11B
수익:
$2.50B
순이익/손실:
$-226.32M
주가수익비율:
-128.15
EPS:
-1.6412
순현금흐름:
$71.51M
1주 성능:
+3.63%
1개월 성능:
+1.54%
6개월 성능:
-11.64%
1년 성능:
+31.43%
1일 변동 폭
$204.16
$211.36
1주일 범위
$200.17
$225.70
52주 변동 폭
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
210.26 | 30.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
473.22 | 179.15B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
176.80 | 124.65B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.16 | 43.45B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
138.75 | 38.14B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
375.70 | 36.52B | 3.77B | 449.25M | 240.68M | 7.8556 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | William Blair | Outperform |
| 2026-01-07 | 개시 | Citigroup | Buy |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-10-27 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | 재개 | Wells Fargo | Equal Weight |
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
Natera adds two oncology experts to board of directors - Investing.com
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors - Yahoo Finance
Did Supreme Court’s Refusal to Hear Natera Appeal Just Shift CareDx’s (CDNA) Investment Narrative? - simplywall.st
Natera expands Austin operations with new sequencing facility - MSN
NTRA & Diakonos partner to use Signatera in refractory melanoma trial - MSN
NTRA Assumed by Wolfe Research -- Rating Upgraded to Outperform - GuruFocus
Wolfe Research initiates Natera stock coverage with outperform rating - Investing.com UK
Natera Inc stock (US6323071042): Wolfe Research initiation and recent price action in focus - AD HOC NEWS
Wolfe Research initiates Natera stock coverage with outperform rating By Investing.com - Investing.com South Africa
[144] Natera, Inc. SEC Filing - Stock Titan
NTRA (NASDAQ: NTRA) insider sells multiple lots, files to resell 3,000 shares - Stock Titan
U.S. Supreme Court rejects CareDx appeal in Natera false-advertising dispute - Reuters
U.S. Supreme Court rejects Natera, CareDx false-advertising dispute - TradingView
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial - Yahoo! Finance Canada
Natera And 2 Other Companies That May Be Trading Below Their Estimated Value - Yahoo Finance
Natera, Inc. (NTRA) Stock Analysis: Impressive Revenue Growth Amidst a Challenging Valuation Landscape - DirectorsTalk Interviews
Natera to launch enhanced Panorama NIPT for low fetal fractions - MSN
Is Natera (NTRA) Quietly Redefining Its Moat With MRD Trials And Sequencing Scale-Up? - Yahoo Finance
Natera’s Solomon Moshkevich on how MRD testing pinpoints cancer recurrence - MedTech Dive
High Growth Tech Stocks in US for May 2026 - simplywall.st
Natera (NTRA) Partners with Diakonos Oncology for Melanoma Trial - GuruFocus
Natera, Diakonos Oncology Pair to Test Molecular Response in Refractory Melanoma Patients - Contract Pharma
Why Natera Is My Favorite Stock Idea for the Rest of 2026 - 24/7 Wall St.
Natera partners with Diakonos for melanoma therapy trial By Investing.com - Investing.com South Africa
Natera partners with Diakonos for melanoma therapy trial - Investing.com UK
Natera's Signatera Selected by Diakonos Oncology for Use in Melanoma Trial - Moomoo
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma - Yahoo Finance
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera president John Fesko sells $291,683 in shares By Investing.com - Investing.com India
Natera president sells $335,091 in company stock By Investing.com - Investing.com India
Natera president sells $335,091 in company stock - Investing.com UK
Natera president John Fesko sells $291,683 in shares - Investing.com
Natera (NTRA) president sells 1,652 shares to cover RSU tax obligations - Stock Titan
Natera (NTRA) president sells 1,438 shares to cover RSU tax withholding - Stock Titan
Natera to Launch Enhanced Panorama NIPT for Low Fetal Fractions - The Globe and Mail
Natera Clinical Milestones Raise Questions On Growth Versus Valuation Risk - Sahm
Citi Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $300 - Moomoo
How Investors May Respond To Natera (NTRA) Boosting Panorama NIPT And Scaling Sequencing Capacity - simplywall.st
Natera (NTRA) Initiates Patient Enrollment for Early-Stage Breas - GuruFocus
Natera’s SIGNAL-ER 101 Study Assesses MRD Testing for ER+ Breast Cancer Treatment Decisions - geneonline.com
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer - The Malone Telegram
Baron Health Care Fund Q1 2026 Portfolio Activity - Seeking Alpha
Natera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue Results (NASDAQ:NTRA) - Seeking Alpha
Natera's EXPAND trial enrollment crosses 2,000 patient milestone - MSN
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.29%
자본화:
|
볼륨(24시간):